Steven A. Wrighton

Steven A. Wrighton's AcademicInfluence.com Rankings

Steven A. Wrighton

Chemistry

#4697

World Rank

#5784

Historical Rank

Chemical Engineering

#613

World Rank

#633

Historical Rank

chemistry Degrees

Download Badge

Chemistry

Steven A. Wrighton's Degrees

PhD Chemical Engineering University of Delaware
Masters Chemical Engineering University of Delaware
Bachelors Chemical Engineering University of Delaware

Why Is Steven A. Wrighton Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Steven A. Wrighton's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression (2001) (2153)
The human hepatic cytochromes P450 involved in drug metabolism. (1992) (964)
The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. (2003) (755)
Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. (1987) (509)
Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. (2002) (470)
Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). (1990) (451)
Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs (2011) (445)
Hepatic CYP2B6 Expression: Gender and Ethnic Differences and Relationship to CYP2B6 Genotype and CAR (Constitutive Androstane Receptor) Expression (2003) (418)
Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. (1994) (415)
CYP3A gene expression in human gut epithelium. (1994) (400)
Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. (1989) (378)
Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. (1994) (375)
The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism*† (2001) (360)
Metabolism and Disposition of the Thienopyridine Antiplatelet Drugs Ticlopidine, Clopidogrel, and Prasugrel in Humans (2010) (355)
In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. (2000) (342)
Identification of an inducible form of cytochrome P-450 in human liver. (1985) (329)
The Conduct of In Vitro and In Vivo Drug‐Drug Interaction Studies: A PhRMA Perspective (2003) (310)
Identification of the cytochrome P-450 induced by macrolide antibiotics in rat liver as the glucocorticoid responsive cytochrome P-450p. (1985) (305)
The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. (2001) (299)
Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation. (1993) (288)
INTERACTIONS OF TWO MAJOR METABOLITES OF PRASUGREL, A THIENOPYRIDINE ANTIPLATELET AGENT, WITH THE CYTOCHROMES P450 (2006) (272)
Identification of a polymorphically expressed member of the human cytochrome P-450III family. (1989) (250)
Molecular and physical mechanisms of first-pass extraction. (1999) (250)
Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. (2002) (243)
Progress in predicting human ADME parameters in silico. (2000) (237)
Metabolism of nicotine by human liver microsomes: stereoselective formation of trans-nicotine N'-oxide. (1992) (212)
Demonstration in multiple species of inducible hepatic cytochromes P-450 and their mRNAs related to the glucocorticoid-inducible cytochrome P-450 of the rat. (1985) (203)
Bimodal distribution of renal cytochrome P450 3A activity in humans. (1996) (199)
Present and future in vitro approaches for drug metabolism. (2000) (199)
THE HUMAN CYP3A SUBFAMILY: PRACTICAL CONSIDERATIONS* (2000) (198)
Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. (1996) (197)
Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. (2002) (192)
Further characterization of the expression in liver and catalytic activity of CYP2B6. (1998) (191)
In vitro methods for assessing human hepatic drug metabolism: their use in drug development. (1993) (186)
Characterization of ethanol-inducible human liver N-nitrosodimethylamine demethylase. (1986) (180)
Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. (1999) (178)
Macrolide antibiotics inhibit the degradation of the glucocorticoid-responsive cytochrome P-450p in rat hepatocytes in vivo and in primary monolayer culture. (1986) (174)
The role of CYP2B6 in human xenobiotic metabolism. (1999) (171)
Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey. (1995) (171)
Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. (2002) (165)
Comparative Metabolic Capabilities and Inhibitory Profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17 (2007) (164)
Induction of cytochrome P-450 by glucocorticoids in rat liver. I. Evidence that glucocorticoids and pregnenolone 16 alpha-carbonitrile regulate de novo synthesis of a common form of cytochrome P-450 in cultures of adult rat hepatocytes and in the liver in vivo. (1984) (160)
The effect of incubation conditions on the enzyme kinetics of udp-glucuronosyltransferases. (2003) (153)
The use of human hepatocyte cultures to study the induction of cytochrome P-450. (1999) (150)
Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. (2002) (146)
Complete cDNA sequence of a cytochrome P-450 inducible by glucocorticoids in human liver. (1986) (143)
Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450. (1993) (143)
An assessment of udp-glucuronosyltransferase induction using primary human hepatocytes. (2004) (142)
The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease (1992) (135)
Identification of the human cytochromes P450 responsible for atomoxetine metabolism. (2002) (134)
Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone. (1998) (132)
Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank. (2000) (132)
Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors. (1999) (130)
Regulation of cytochrome P-450p by phenobarbital and phenobarbital-like inducers in adult rat hepatocytes in primary monolayer culture and in vivo. (1986) (130)
Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily. (1994) (129)
The Biotransformation of Prasugrel, a New Thienopyridine Prodrug, by the Human Carboxylesterases 1 and 2 (2008) (123)
Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. (1999) (119)
The human drug metabolizing cytochromes P450 (1996) (113)
Identification of a human liver cytochrome P-450 homologous to the major isosafrole-inducible cytochrome P-450 in the rat. (1986) (108)
Purification and characterization of ethanol-inducible human hepatic cytochrome P-450HLj. (1987) (107)
Ethanol and isopentanol increase CYP3A and CYP2E in primary cultures of human hepatocytes. (1995) (106)
In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. (1996) (102)
Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors. (2000) (101)
Role of cytochrome P450 2C9 and an allelic variant in the 4'-hydroxylation of (R)- and (S)-flurbiprofen. (1995) (100)
Examination of purported probes of human CYP2B6. (1997) (98)
Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6. (1999) (98)
In vitro human tissue models in risk assessment: report of a consensus-building workshop. (2001) (96)
Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor. (1996) (94)
Isolation and characterization of human fetal liver cytochrome P450HLp2: a third member of the P450III gene family. (1989) (89)
Stereoselective sulfoxidation of sulindac sulfide by flavin-containing monooxygenases. Comparison of human liver and kidney microsomes and mammalian enzymes. (2000) (89)
The Use of In Vitro Metabolism Techniques in the Planning and Interpretation of Drug Safety Studies (1995) (87)
Effect of Tadalafil on Cytochrome P450 3A4–mediated Clearance: Studies in Vitro and in Vivo (2005) (87)
Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine. (2001) (86)
Coinduction of multiple hepatic cytochrome P-450 proteins and their mRNAs in rats treated with imidazole antimycotic agents. (1989) (85)
Effects of Antipsychotic Drugs on Ito, INa, Isus, IK1, and hERG: QT Prolongation, Structure Activity Relationship, and Network Analysis (2006) (84)
Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors. (1999) (83)
Studies of flurbiprofen 4'-hydroxylation. Additional evidence suggesting the sole involvement of cytochrome P450 2C9. (1996) (81)
Binding and metabolism of benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene by seven purified forms of cytochrome P-450. (1984) (81)
STOCHASTIC PREDICTION OF CYP3A-MEDIATED INHIBITION OF MIDAZOLAM CLEARANCE BY KETOCONAZOLE (2006) (80)
Comparison of human and rhesus monkey in vitro phase I and phase II hepatic drug metabolism activities. (1993) (79)
Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity. (2007) (78)
Induction of cytochrome P4503A by taxol in primary cultures of human hepatocytes. (1998) (78)
Inhibition of Human CYP3A Catalyzed 1′-Hydroxy Midazolam Formation by Ketoconazole, Nifedipine, Erythromycin, Cimetidine, and Nizatidine (1994) (77)
First-pass midazolam metabolism catalyzed by 1alpha,25-dihydroxy vitamin D3-modified Caco-2 cell monolayers. (1999) (73)
Biotransformation of alprazolam by members of the human cytochrome P4503A subfamily. (1999) (73)
Involvement of Toll-like receptor 4 in acetaminophen hepatotoxicity. (2006) (72)
Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine. (1996) (72)
Application of in silico approaches to predicting drug--drug interactions. (2001) (70)
Autoactivation and activation of the cytochrome P450s. (1998) (70)
Contribution of human CYP3A subfamily members to the 6-hydroxylation of chlorzoxazone. (1997) (70)
Characterization of the Expression and Activity of Carboxylesterases 1 and 2 from the Beagle Dog, Cynomolgus Monkey, and Human (2011) (70)
Detection of human lung cytochromes P450 that are immunochemically related to cytochrome P450IIE1 and cytochrome P450IIIA. (1992) (69)
Procarcinogen activation by cytochrome P450 3A4 and 3A5 expressed in Escherichia coli and by human liver microsomes. (1995) (68)
Cytochrome P-450 complex formation by dirithromycin and other macrolides in rat and human livers (1993) (68)
Synthesis and degradation of 3-methylcholanthrene-inducible cytochromes P-450 and their mRNAs in primary monolayer cultures of adult rat hepatocytes. (1985) (67)
PhRMA White Paper on ADME Pharmacogenomics (2008) (67)
The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity. (2002) (66)
Purification of a human liver cytochrome P-450 immunochemically related to several cytochromes P-450 purified from untreated rats. (1987) (65)
Role of CYP3A and CYP2E1 in Alcohol-Mediated Increases in Acetaminophen Hepatotoxicity: Comparison of Wild-Type and Cyp2e1(–/–) Mice (2007) (62)
In vitro-in vivo correlations of human (S)-nicotine metabolism. (1995) (61)
Effect of arsenite on induction of CYP1A, CYP2B, and CYP3A in primary cultures of rat hepatocytes. (1999) (61)
Stereo- and regioselective N- and S-oxidation of tertiary amines and sulfides in the presence of adult human liver microsomes. (1993) (61)
Effect of fluoxetine, norfluoxetine, sertraline and desmethyl sertraline on human CYP3A catalyzed 1'-hydroxy midazolam formation in vitro. (1995) (60)
Degradation of rat liver cytochromes P450 3A after their inactivation by 3,5-dicarbethoxy-2,6-dimethyl-4-ethyl-1,4-dihydropyridine: characterization of the proteolytic system. (1992) (60)
Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation (1997) (59)
Atomoxetine Hydrochloride: Clinical Drug-Drug Interaction Prediction and Outcome (2004) (59)
Predictions of the In Vivo Clearance of Drugs from Rate of Loss Using Human Liver Microsomes for Phase I and Phase II Biotransformations (2006) (59)
Role of CYP3A in ethanol-mediated increases in acetaminophen hepatotoxicity. (1997) (58)
Genetic Polymorphisms in Human Proton-Dependent Dipeptide Transporter PEPT1: Implications for the Functional Role of Pro586 (2004) (58)
Identification of a cytochrome P-450 in human fetal liver related to glucocorticoid-inducible cytochrome P-450HLp in the adult. (1988) (58)
Inhibition of benzo(a)pyrene and benzo(a)pyrene 7,8-dihydrodiol metabolism by benzo(a)pyrene quinones. (1979) (57)
Prediction of CYP3A-Mediated Drug-Drug Interactions Using Human Hepatocytes Suspended in Human Plasma (2011) (57)
Immunochemical evidence for multiple steroid-inducible hepatic cytochromes P-450 in the rat. (1987) (57)
Alcohol-mediated increases in acetaminophen hepatotoxicity: role of CYP2E and CYP3A. (1998) (54)
Degradation of rat hepatic cytochrome P-450 heme by 3,5-dicarbethoxy-2,6-dimethyl-4-ethyl-1,4-dihydropyridine to irreversibly bound protein adducts. (1987) (53)
COMPARATIVE METABOLIC CAPABILITIES OF CYP 3 A 4 , CYP 3 A 5 , AND CYP 3 A 7 (2002) (52)
Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes. (1994) (48)
Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia (1992) (48)
Alterations of the catalytic activities of drug-metabolizing enzymes in cultures of human liver slices. (1998) (48)
Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomes. (1996) (47)
Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation (2000) (47)
Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes. (2012) (43)
ROLE OF THE NUCLEAR RECEPTOR PREGNANE X RECEPTOR IN ACETAMINOPHEN HEPATOTOXICITY (2005) (42)
Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia. (1992) (42)
Inactivation of multiple hepatic cytochrome P-450 isozymes in rats by allylisopropylacetamide: mechanistic implications. (1987) (41)
Liquid chromatography/nuclear magnetic resonance spectroscopy and liquid chromatography/mass spectrometry identification of novel metabolites of the multidrug resistance modulator LY335979 in rat bile and human liver microsomal incubations. (1998) (41)
Estrogen Regulation of the Cytochrome P450 3A Subfamily in Humans (2004) (39)
Midazolam metabolism by modified Caco-2 monolayers: effects of extracellular protein binding. (1999) (39)
The effect of hormone replacement therapy on CYP3A activity (2000) (38)
In Vitro Metabolism: Subcellular Fractions (1999) (37)
Pharmacogenomics of Gemcitabine Metabolism: Functional Analysis of Genetic Variants in Cytidine Deaminase and Deoxycytidine Kinase (2013) (37)
Differential apoprotein loss of rat liver cytochromes P450 after their inactivation by 3,5-dicarbethoxy-2,6-dimethyl-4-ethyl-1,4-dihydropyridine: a case for distinct proteolytic mechanisms? (1992) (37)
Apparent High CYP3A5 Expression Is Required for Significant Metabolism of Vincristine by Human Cryopreserved Hepatocytes (2008) (37)
Predictions of Cytochrome P450-Mediated Drug-Drug Interactions Using Cryopreserved Human Hepatocytes: Comparison of Plasma and Protein-Free Media Incubation Conditions (2012) (37)
Acetaminophen hepatotoxicity precipitated by short-term treatment of rats with ethanol and isopentanol: protection by triacetyloleandomycin. (2000) (36)
Effect of Taxol on cytochrome P450 3A and acetaminophen toxicity in cultured rat hepatocytes: comparison to dexamethasone. (1997) (36)
A novel testosterone 6 beta-hydroxylase activity assay for the study of CYP3A-mediated metabolism, inhibition, and induction in vitro. (2001) (33)
Distribution of cytochromes P-450, cytochrome b5, and NADPH-cytochrome P-450 reductase in an entire human liver. (1990) (33)
Comparison of human and monkey peptide transporters: PEPT1 and PEPT2. (2004) (33)
Biosynthesis of drug glucuronides for use as authentic standards. (2002) (33)
Genomic analysis of the carboxylesterases: identification and classification of novel forms. (2010) (32)
Metabolism of phenytoin by the gingiva of normal humans: The possible role of reactive metabolities of phenytoin in the initiation of gingival hyperplasia (1996) (32)
Reversible mechanisms of enzyme inhibition and resulting clinical significance. (2014) (31)
PharmGKB Update: II. CYP3A5, Cytochrome P450, Family 3, Subfamily A, Polypeptide 5 (2004) (31)
Flavin-containing monooxygenase-mediated N-oxidation of the M(1)-muscarinic agonist xanomeline. (1999) (30)
Evaluation of an in vitro coculture model for the blood-brain barrier: Comparison of human umbilical vein endothelial cells (ECV304) and rat glioma cells (C6) from two commercial sources (1999) (30)
ARSENITE DECREASES CYP3A4 AND RXRα IN PRIMARY HUMAN HEPATOCYTES (2005) (29)
In vitro metabolism of zatosetron. Interspecies comparison and role of CYP 3A. (1994) (28)
Potentially increasing the metabolic stability of drug candidates via computational site of metabolism prediction by CYP2C9: The utility of incorporating protein flexibility via an ensemble of structures. (2011) (26)
Short-term treatment with alcohols causes hepatic steatosis and enhances acetaminophen hepatotoxicity in Cyp2e1(-/-) mice. (2000) (25)
Human liver lauric acid hydroxylase activities. (1995) (24)
Characterization of a unique aldo-keto reductase responsible for the reduction of chlordecone in the liver of the gerbil and man. (1986) (23)
Effect of caffeine on acetaminophen hepatotoxicity in cultured hepatocytes treated with ethanol and isopentanol. (2002) (22)
Effect of buffer components and carrier solvents on in vitro activity of recombinant human carboxylesterases. (2008) (22)
Two monoclonal antibodies recognizing different epitopes on rat cytochrome IIB1 react with human IIE1. (1992) (21)
Physiological approaches to the prediction of drug-drug interactions in study populations. (2003) (21)
Predicting drug interactions and pharmacokinetic variability with in vitro methods: the olanzapine experience. (1999) (20)
Characterization by liquid chromatography-nuclear magnetic resonance spectroscopy and liquid chromatography-mass spectrometry of two coupled oxidative-conjugative metabolic pathways for 7-ethoxycoumarin in human liver microsomes treated with alamethicin. (2002) (19)
Demonstration of two unique metabolites of arachidonic acid from phorbol ester-stimulated bovine lymphocytes. (1983) (19)
Arsenite decreases CYP3A4 and RXRalpha in primary human hepatocytes. (2005) (18)
Protection of ethanol-mediated acetaminophen hepatotoxicity by triacetyloleandomycin, a specific inhibitor of CYP3A. (1997) (18)
Pharmacokinetic (PK) and pharmacodynamic (PD) interactions between fluvoxamine and olanzapine (1997) (17)
Interactions of peroxyquinols with cytochromes P450 2B1, 3A1, and 3A5: influence of the apoprotein on heterolytic versus homolytic O-O bond cleavage. (1995) (17)
Catalysis of the cysteine conjugation and protein binding of acetaminophen by microsomes from a human lymphoblast line transfected with the cDNAs of various forms of human cytochrome P450. (1997) (17)
Role of mouse CYP2E1 in the O-hydroxylation of p-nitrophenol: comparison of activities in hepatic microsomes from Cyp2e1(-/-) and wild-type mice. (2004) (16)
COMPARATIVE METABOLIC CAPABILITIES AND INHIBITORY PROFILES OF CYP 2 D 6 . 1 , CYP 2 D 6 . 10 , AND CYP 2 D 6 . 17 (2007) (16)
Modulation of the induction of rat hepatic cytochromes P-450 by selenium deficiency. (1989) (16)
Arsenic decreases RXRα-dependent transcription of CYP3A and suppresses immune regulators in hepatocytes. (2012) (15)
Arsenite decreases CYP3A23 induction in cultured rat hepatocytes by transcriptional and translational mechanisms. (2005) (14)
Erratum: Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: Lack of prediction by the erythromycin breath test (Drug Metabolism and Disposition (1994) 22 (947-955)) (1995) (13)
Effect of Dirithromycin on Human CYP3A In Vitro and on Pharmacokinetics and Pharmacodynamics of Terfenadine In Vivo (1996) (13)
Hepatic catecholestrogen synthases: Differential effect of sex, inducers of cytochromes P-450 and of antibody to the glucocorticoid inducible cytochrome P-450 on NADPH-dependent estrogen-2-hydroxylase and on organic hydroperoxide-dependent estrogen-2/4-hydroxylase activity of rat hepatic microsomes (1990) (13)
Liver Dihydropyrimidine Dehydrogenase Activity in Human, Cynomolgus Monkey, Rhesus Monkey, Dog, Rat and Mouse (1998) (12)
A Population Approach to Enzyme Characterization and Identification: Application to Phenacetin O-Deethylation (2000) (11)
Rapid acceleration of deoxyglucose transport by phorbol esters in bovine lymphocytes. (1982) (11)
The interactions of a selective protein kinase C beta inhibitor with the human cytochromes P450. (2002) (10)
Modulation of rat hepatic cytochromes P450 by chronic methapyrilene treatment. (1991) (9)
Inhibition of rat methylbenzylnitrosamine metabolism by dietary zinc and zinc in vitro. (1992) (9)
Drug-Drug Interactions and the Cytochromes P450 (2003) (9)
Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials. (2010) (9)
THE USE OF A SUBSTRATE CASSETTE STRATEGY TO IMPROVE THE CAPACITY AND THROUGHPUT OF CYTOCHROME P450 INDUCTION STUDIES IN HUMAN HEPATOCYTES (2005) (8)
Three-Dimensional-Quantitative Structure Activity Relationship Analysis of Cytochrome P-450 3 A 4 Substrates (1999) (7)
Dissection of the Early Molecular Events in the Activation of Lymphocytes by 12-0-Tetradecanoylphorbol-13-Acetate (1980) (6)
Mechanism of arsenite-mediated decreases in CYP3A23 in rat hepatocytes. (2005) (5)
Purification and characterization of aldo-keto reductases from gerbil liver: immunochemical evidence for related proteins in other mammalian species. (1986) (3)
Predictions of CYP-Mediated Drug-Drug Interactions Using Cryopreserved Human Hepatocytes: Comparison of Plasma and Protein-Free Media Incubation Conditions (2012) (3)
Effect of proteasome inhibition on toxicity and CYP3A23 induction in cultured rat hepatocytes: comparison with arsenite. (2006) (3)
Degradation of cytochrome P-450 (DEX) is inhibited by troleandomycin in primary monolayer cultures of adult rat hepatocytes (1984) (2)
REGULATION OF DNA MODIFICATION BY SELECTIVE CONJUGATION OF BENZO(a)PYRENE METABOLITES (1980) (2)
Three-Dimensional Quantitative Structure Activity Relationship Analyses of Substrates for CYP 2 B 6 (1998) (2)
Characteristics of microsomal reduction of benzo[a]pyrene 4,5-oxide. (1982) (2)
ARSENITE DECREASES CYP 3 A 4 AND RXR IN PRIMARY HUMAN HEPATOCYTES (2005) (2)
Protection o f Ethanol-mediated Acetaminophen Hepatotoxicity by Triacetyloleandomycin , a Specific Inhibitor or CYP 3 A * (2015) (1)
Involvement of multiple cytochrome p450 isoforms in naproxen demethylation (1996) (1)
Reversible Mechanisms of Enzyme Inhibition and Resulting Clinical Significance. (2021) (1)
The Effect of Estrogen Replacement Therapy on CYP3A Activity (1999) (1)
Nonuniform distribution of cytochrome P450IA2 in liver. (1991) (1)
Stereoselective disposition of the enantiomers of the benzoquinolinone LY191704, a human type I 5 alpha-reductase inhibitor. Differences between rats and dogs. (1996) (1)
Stimulation in vitro of midazolam (MDZ) metabolism by CYP3A4 (1996) (0)
ffect of tadalafil on cytochrome P 450 A 4 – mediated clearance : Studies in vitro nd in vivo (2004) (0)
Projection of doses for QT‐prolongation studies based on modeling of the worst‐case inhibition of CYP3A (2005) (0)
Phenytoin metabolism by gingiva from normal humans (1997) (0)
Glossary and tutorial of xenobiotic metabolism terms used during small molecule drug discovery and development (IUPAC Technical Report) (2021) (0)
Prasugrel in Humans Metabolism and Disposition of the Thienopyridine Antiplatelet Drugs Ticlopidine , Clopidogrel , and (2009) (0)
Prediction of CYP3A inhibition using physiologically‐based pharmacokinetic modeling and trial simulation (2003) (0)
Regulation of cytochrome P-450j in rat hepatocytes in vivo and in primry monolayer culture (1987) (0)
MASS SPECTROMETRY IDENTIFICATION OF NOVEL METABOLITES OF THE MULTIDRUG RESISTANCE MODULATOR LY 335979 IN RAT BILE AND HUMAN LIVER MICROSOMAL INCUBATIONS (1998) (0)
Microsoft Word-32394427-file00.docx (2012) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Steven A. Wrighton?

Steven A. Wrighton is affiliated with the following schools:

Virginia Commonwealth University